Ivacaftor Therapy in CF Patients: Single Center Experience

Ivacaftor is the first novel cystic fibrosis pharmaceutical that acts at the molecular level to potentiate cystic fibrosis transmembrane conductance regulator (CFTR) function and was first approved for clinical use in 2012. We are sharing our single center experience of five patients: four from pedi...

Descripción completa

Detalles Bibliográficos
Autores principales: Mondal, Pritish, Loyson, Amber, Lascano, Jorge, Hegde, Satyanarayan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4590953/
https://www.ncbi.nlm.nih.gov/pubmed/26556432
http://dx.doi.org/10.1155/2014/947923

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4590953/
https://www.ncbi.nlm.nih.gov/pubmed/26556432
http://dx.doi.org/10.1155/2014/947923

Ejemplares similares